if you have any.
HPV vaccines
Vaccines are being developed to prevent HPV infection. There are many different HPV strains. Some are known to be high risk for cervical cancer. If we had effective vaccines against all these strains, we might be able to prevent cervical cancer altogether. Several research trials have been testing vaccines as a way of preventing infection with HPV.
A trial testing Gardasil called FUTURE II reported its results in October 2005. This phase 3 trial involved over 12,000 women aged between 16 and 26. These women did not have HPV before the start of the trial. The women were divided into two groups. Half the women were given Gardasil and the other half had a dummy vaccine (placebo). Both groups of women had 3 injections of either the vaccine or placebo over six months. Over the following two years the women had regular checks to see if they had developed HPV, or had any precancerous changes to the cells of the cervix, which could develop into a cancer. The group who had the vaccine showed no precancerous changes. Of the 5,258 women who had the placebo, 21 had precancerous changes, which is 0.4%. The researchers found that Gardasil protected against HPV types 6 and 11, as well as 16 and 18. Gardasil was licensed for use within the European Union in September 2006.
Two other phase 3 trials have tested the vaccine Cervarix. The first was for women under 26 and closed in July 2005. It involved over 18,000 women from all over the world, including the UK. This study was called ‘PATRICIA’ (PApilloma TRIal to prevent Cervical cancer In young Adults). The second was for women of 26 and over, and closed in August 2006. The aim of the trial is to find out the effect of the Cervarix vaccine on long term HPV infection. So it will be some time before we know the results.
It is possible that these vaccines will be used in a national vaccination programme in the UK in the future. The research suggests that they would dramatically lower the number of cases of cervical cancer. They would also reduce the need for colposcopy. At the moment, they are only available on private prescription. There is more information about HPV vaccines and cervical cancer in the cervical cancer questions and answers section of CancerHelp UK.
http://www.cancerhelp.org.uk/help/default_printer_friend.asp?page=9596merck is not the only company who developed this vaccine -- a french drug company was also the developer
Comparable strategies needed to evaluate human papillomavirus vaccine efficiency across Europe
K Soldan1 (kate.soldan@hpa.org.uk), J Dillner2
1Health Protection Agency Centre for Infections, London, United Kingdom
2Dept of Medical Microbiology, MAS University Hospital, Lund University, Malmö, Sweden
A quadrivalent vaccine against human papillomavirus (HPV) types 16, 18, 6 and 11, known as GardasilTM (or Silgard, see note) was granted a marketing license by the European Commission in September 2006 following the positive opinion of the European Medicines Agency’s (EMEA) Committee for Medicinal Products for Human Use in July 2006 <1>.
HPV infection is the most frequent sexually transmitted infection in Europe. Certain HPV types have been established as causative agents of cervical cancer (and its precursor stages that are the target of cervical screening), as well as of some other rare cancers of the ano-genital tract and oral cavity. A meta-analysis of published studies found just over 70% of invasive cervical cancer cases in Europe to be positive for HPV types 16 or 18 <2>. Pre-cancerous stages of cervical disease are common and often resolve with time. However, their follow-up, including treatment, repeated screening and examination of the cervix (colposcopy), is associated with considerable costs and anxiety. HPV 6 and 11 are not causally linked to cervical cancer, but are associated with some low-grade cervical lesions, the vast majority of genital warts and the rare condition of recurrent respiratory papillomatosis <3>.
The Gardasil vaccine is composed of virus-like particles (VLP) generated by the synthesis and self-assembly of the major HPV capsid protein (L1) in yeast cells (Saccharomyces cerevisiae). Gardasil has been licensed for the prevention of high-grade cervical intraepithelial neoplasia (CIN grades 2 and 3), cervical cancer, high-grade vulvar intraepithelial neoplasia (VIN grades 2 and 3), and external genital warts (condyloma acuminata) causally associated with HPV types 6, 11, 16, and 18 <1>. Trials have been undertaken to demonstrate the efficacy of the vaccine in women aged 16 to 26 years and immunogenicity in girls and boys aged 9 to 15 years. Protective efficacy in males has not been reported in the literature yet, but the results of more trials involving males are expected over the next few years.
Another vaccine composed of virus-like particles (VLP), a bivalent vaccine for HPV 16 and 18, manufactured by GlaxoSmithKline, is currently under evaluation by the EMEA. Both these prophylactic vaccines have been shown to have very high efficacy in uninfected women against infection, cervical intraepithelial neoplasia and, by implication, against cervical cancer caused by the HPV types targeted by the vaccine <4>.
The availability of efficacious vaccines now means that vaccination strategies should be designed and evaluated to inform decisions on efficient control of HPV-related diseases. Several questions about HPV vaccination efficacy and effectiveness are still under consideration <5> For example, data on its efficacy against disease in males and in women aged over 26 years (of whom many could have been previously infected) are still awaited. A longer follow-up of vaccine programmes is needed to determine the duration of protection. The impact of vaccination on the epidemiology and disease burden of HPV types not covered by the vaccine is also uncertain. There are some data from trials which suggest cross-protection against HPV-types closely related to the vaccine types. The possibility of type-replacement with non-vaccine types emerging as the cause of more disease is also a concern to be evaluated further. It is likely that most European countries will first consider vaccination of girls who have not yet become sexually active
http://www.eurosurveillance.org/ew/2006/061123.aspregarding the stigma around hpv --
Social Stigma
"There is unfortunately a social stigma associated with cervical cancer because HPV is a direct cause in approximately 70% of cases," Dr. Makhija told Medscape. "People are under the impression that this means the patient slept around or was in some way more sexually active, but this is often not the case, and she may well have been with 1 person who had the infection."
HPV is the most common sexually transmitted infection in the US. The Centers for Disease Control and Prevention estimates that about 6.2 million Americans become infected with HPV every year and that over half of all sexually active men and women become infected at some time in their lives.
"Our expectation is that the far-right machine will gear up its disinformation and fearmongering tactics, all aimed at reducing availability of the vaccine by threatening funding and clouding the facts regarding the safety and the need for this vaccine," Ms. Julie Kay, an attorney for Legal Momentum, a New York City–based women's-rights organization, said in a statement to the press.
But Dr. Makhija said she has been pleasantly surprised by reaction so far. "I think people are realizing that this is not a political issue so much as a health issue." Based in Alabama, the investigator had worried about how difficult it might be to recruit women in the Deep South for the trial. "But we enjoyed an enormous response and had no trouble at all," she said. "People realized that this is something that could potentially protect their daughters, and the response has been excellent."
"Exciting Win Against Cancer"
Mr. Alan Kaye, from the National Cervical Cancer Coalition in Van Nuys, California, called the news "an exciting win against cancer." He is looking forward to what this could mean for public health.
But he is also glad from a personal perspective. Mr. Kaye founded the cancer coalition with his wife before she died of cancer. Today is the 5-year anniversary of her death. "It's wonderful to think that this amazing step forward has taken place on such an important day," he said. "My wife would be pleased."
http://www.brodstonehospital.org/your%20health.htmother countries approve gardasil --
During an interview with Medscape, Jaime de la Garza, MD, from the Instituto Nacional de Cancerología in Tlapan, Mexico, agreed that the vaccines represent an important advance. He says they will be especially important for women in developing countries. "The incidence of cervical cancer is continuing to rise, and mortality rates are especially high in poor countries. If we can get vaccines such as these to patients, it will make a big difference."
Gardasil was approved last week for use in Mexico and is currently under review with regulatory agencies in the European Union, Argentina, Australia, Brazil, New Zealand, Singapore, and Taiwan.
http://www.brodstonehospital.org/your%20health.htmthis from an interview with dr tristram in the uk
Dr Tristram said, "This vaccine has to be given as a preventative, before there is any contact with the virus.
"If we are looking at the population and asking who should be vaccinated, we have to consider that one in four young people are sexually active before the age of 16, so we have to look at a younger age group.
"Another issue to consider is that, at around the time of puberty, if the cervix comes into contact with HPV, it is more likely to cause problems."
more --
Q Will the vaccine replace the need for regular smear tests?
A Dr Tristram said, "Cervical screening has been very successful in reducing the incidence of cervical cancer and this should not stop just because a vaccine has been introduced.
"There are lots of different types of HPV which can cause cervical cancer, not just 16 and 18, for which the current vaccine offers protection.
"The vaccine will reduce the incidence of cervical cancer further, but it will not get rid of it."
it also looks like some hpv related cancers are becoming MORE virulent and difficult to treat.
meps' in the uk supporting the use of gardasil
glynis wilmot is the labour mep for the west midlands
Cutting cancer deaths
I reported in the October edition that European Commission had licensed Gardasil, the first vaccine against HPV which can lead to cervical cancer.
I am pressing the Commission on its plans to ensure that vaccination programmes are introduced in all member states, as well as a comprehensive programme of education to inform parents about the vaccine. Immunising every 12 year old girl could cut deaths from cervical cancer by more than 75%.
Latest information
http://www.gleniswillmott.labour.co.uk/ViewPage.cfm?Page=20338planned parenthood's statement on gardasil
Planned Parenthood Applauds FDA Approval of Gardasil
HPV Vaccine Is Crucial Step Forward for Women's Health
New York, NY — Planned Parenthood Federation of America (PPFA) commended today's action by the U.S. Food and Drug Administration (FDA), which approved the first vaccine against two types of human papilloma virus (HPV) that cause about 70 percent of cervical cancer cases.
"This is a huge step forward for women’s health. Prevention is the key to good health, and this vaccine will give future generations the promise of health, safety and peace of mind," said PPFA President Cecile Richards. “Now we must move forward to educate the public about the vaccine and ensure it is available to all Americans, regardless of their income level.”
Planned Parenthood provides more than 1,000,000 women with cancer screenings each year. This new vaccine will hopefully save lives.
"The HPV vaccine is a public health breakthrough," said Richards. "On behalf of the millions of women, men and teens Planned Parenthood serves every year, I thank the FDA for today's action."
Worldwide, cervical cancer is the second leading cause of cancer deaths among women. Each year approximately 10,000 cases of cervical cancer are diagnosed in the United States, and 4,000 American women die from the disease.
###
http://ww1.ppgi.org/includes/media/prjune_06_c.aspcanada approves gardasil{ but of course merck has subverted the entire world to it's sinister plans}
HPV VACCINE APPROVED
In July 2006, a new vaccine to prevent against four strains of the Human Papilloma Virus was approved for use in Canada by Health Canada. Gardasil will be available by the end of August 2006 through Canadian physicians and pharmacists, and is designed to prevent cervical, vulvar, and vaginal cancer as well as genital warts.
For more information, please visit:
http://www.cdc.gov/std/hpv/STDFact-HPV-vaccine.htm.http://www.optionsforsexualhealth.org/